Argenica Therapeutics Ltd
Argenica Therapeutics Limited is an Australia-based clinical-stage biotechnology company.
The business
Argenica Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company develops neuroprotective therapeutics for patients following stroke and other acute neurological injuries. Its drug candidate, ARG-007, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed a Phase II clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions. The ARG-007 has a plurifunctional mechanism of action, affecting neuronal excitotoxicity, calcium influx and mitochondrial dysfunction, and reducing the activation of damaging proteolytic enzymes which enhances its neuroprotective potential and translational clinical effectiveness.
Small Caps Research
No research on Argenica Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise AGN based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Argenica Therapeutics Releases Positive Safety Data from Phase 2 ARG-007 Stroke Trial
Perth-based biotech Argenica Therapeutics (ASX: AGN) has released top-line safety results from its Phase 2 trial evaluating lead candidate ARG-007 on patients with acute ischaemic stroke (AIS) who are undergoing mechanical removal of a blood clot in the brain. The multi-centre, double-blind, randomised, placebo-controlled, single-dose clinical study conducted by the company’s clinical research organisation ProPharma […]
Argenica Therapeutics gains ethics approval for phase 1 clinical trial of stroke drug ARG-007
Perth-based biotechnology company Argenica Therapeutics (ASX: AGN) has gained ethics approval to commence a pivotal phase 1 clinical trial of lead drug ARG-007 in healthy participants. ARG-007 is being developed as a novel therapeutic to reduce brain tissue death after stroke with potential to enhance recovery once a stroke has taken place. Approval for the […]
Argenica Therapeutics reports positive findings from peer-reviewed study of stroke drug ARG-007
Biotechnology company Argenica Therapeutics (ASX: AGN) has announced positive findings from an international peer-reviewed study assessing the safety of its lead drug ARG-007 to reduce brain tissue death after stroke. The study was published in the online Journal of Biochemistry and Biophysics Reports by Argenica chief scientific officer Professor Bruno Meloni, in partnership with research […]
Argenica Therapeutics tops up bank balance with $5.5m placement to advance ARG-007 in other neurological conditions
Argenica Therapeutics (ASX: AGN) has topped up its cash reserves with a $5.5 million placement to advance development of its lead drug ARG-007 for other applications beyond stroke. The move follows a number of successful pre-clinical studies evaluating ARG-007 in hypoxic-ischaemic encephalopathy (HIE), traumatic brain injury (TBI), and global cerebral ischaemia. According to Argenica, the […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.